文献速递精神分裂症与精神病性障碍

氯氮平与其他抗精神病药安全性比较:系统综述与荟萃分析

Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis.
PubMed 文献 · Br J Psychiatry · 2025-10-28

该研究纳入116项随机对照试验(n=8431),比较氯氮平与其他抗精神病药的安全性。单药治疗中,氯氮平不增加死亡或不良反应停药风险,但增加癫痫和直立性低血压/心动过缓/晕厥风险,粒细胞缺乏症风险接近三倍但置信区间宽。联合治疗未增加严重不良事件风险。

要点

  • 氯氮平单药治疗不增加死亡风险(RR 1.01)或不良反应停药风险(RR 1.18)。
  • 氯氮平增加癫痫风险(RR 3.61)和直立性低血压/心动过缓/晕厥风险(RR 1.66)。
  • 氯氮平联合治疗未增加严重不良事件风险,但需监测。

核心结论

  • 氯氮平致死性不良事件仍罕见,在适当监测下安全性支持更广泛和更早期使用。

研究设计与样本

  • 系统检索MEDLINE、CENTRAL、Embase、PsycINFO、ClinicalTrials.gov和WHO ICTRP至2024年10月10日,纳入比较氯氮平(单药或联合)与其他抗精神病药的随机对照试验,评估37种不良结局。

主要发现

  • 共纳入116项RCT(n=8431);69项单药RCT(n=6281)中,氯氮平不增加死亡风险(RR 1.01,95%CI 0.50-2.01,患病率0.1%)或不良反应停药风险(RR 1.18,95%CI 0.91-1.53,患病率7.2%)。
  • 粒细胞缺乏症风险接近三倍(RR 2.81,95%CI 0.97-8.12,患病率0.7%),但置信区间宽。
  • 氯氮平增加癫痫风险(RR 3.61,95%CI 1.80-7.95,患病率3.1%)和直立性低血压/心动过缓/晕厥风险(RR 1.66,95%CI 1.00-2.77,患病率11%)。
  • 心肌炎/心肌病无差异(RR 0.33,95%CI 0.01-8.13);氯氮平增加白细胞减少、流涎、镇静、心动过速、高血压、便秘、恶心/呕吐、发热、流感样综合征和头痛风险。
  • 47项联合治疗RCT(n=2150)中,氯氮平联合未增加严重不良事件风险;明确评估的试验中无粒细胞缺乏症(21项RCT,n=894)或癫痫(8项RCT,n=313)病例报告。

临床怎么用

  • 临床使用氯氮平时应监测癫痫和直立性低血压/心动过缓/晕厥,并继续关注粒细胞缺乏症风险。
  • 联合治疗时严重不良事件风险未增加,但仍需适当监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotics are first-line treatments for schizophrenia, yet many patients show inadequate response. Clozapine, the gold standard for treatment-resistant schizophrenia, remains underutilised due to safety and monitoring concerns. AIMS: To evaluate the adverse effects of clozapine in schizophrenia through a meta-analysis of randomised controlled trials (RCTs). METHOD: We systematically searched MEDLINE, CENTRAL, Embase, PsycINFO, ClinicalTrials.gov and WHO ICTRP up to 10 October 2024 for RCTs comparing clozapine (as either monotherapy or combination therapy) with other antipsychotics. We assessed 37 distinct adverse outcomes. Risk ratios were calculated for dichotomous outcomes and standardised mean differences for continuous outcomes, with confidence intervals. RESULTS: A total of 116 RCTs (n = 8431) were included. In 69 monotherapy RCTs (n = 6281), clozapine showed no difference in either mortality (risk ratio 1.01, 95% CI: 0.50, 2.01, prevalence 0.1%) or discontinuation due to adverse effects (risk ratio 1.18, 95% CI: 0.91, 1.53, prevalence 7.2%). Agranulocytosis risk was nearly tripled (risk ratio 2.81, 95% CI: 0.97, 8.12, prevalence 0.7%), although with wide confidence intervals. Clozapine increased the risk of seizures (risk ratio 3.61, 95% CI: 1.80, 7.95, prevalence 3.1%) and orthostatic hypotension/bradycardia/syncope (risk ratio 1.66, 95% CI: 1.00, 2.77, prevalence 11%). No difference was found for myocarditis/cardiomyopathy (risk ratio 0.33, 95% CI: 0.01, 8.13). Clozapine increased the risk of leukopenia, hypersalivation, sedation, tachycardia, hypertension, constipation, nausea/vomiting, fever, flu-like syndrome and headache. In 47 combination RCTs (n = 2150), clozapine combinations were not associated with increased risk of severe adverse effects; no cases of agranulocytosis (21 RCTs, n = 894) or seizures (8 RCTs, n = 313) were reported in trials that explicitly assessed these outcomes. CONCLUSIONS: Life-threatening adverse events remain rare with clozapine. With appropriate monitoring, its safety profile supports broader and potentially earlier use. Future studies should refine monitoring protocols and explore additional indications.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pinioti E, Glarou E, Lappas AS, et al. Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis. Br J Psychiatry. 2025. PMID: 41146456. doi:10.1192/bjp.2025.10421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。